Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Roche CEO opposes Novo Holdings' acquisition of Catalent, urging for it to be blocked. Roche exceeded Q3 sales expectations, driven by the success of drugs like Ocrevus and Vabysmo. Pfizer's RSV vaccine has been approved by the FDA for a wider adult population. Novo Nordisk has raised concerns with the FDA about the complexity of compounders producing its drug Semaglutide. Alto Neuroscience's depression treatment did not meet expectations in a mid-stage trial, echoing Acelyrin's setback last year. Trilink Biotechnologies has launched customized mRNA sets for screening studies. Updates on Trodelvy's withdrawal for bladder cancer, Sage Therapeutics' layoffs, and more are also featured. Pfizer has downsized with 75 job cuts at a North Carolina site. Opportunities in the life sciences industry are also highlighted.Thank you for listening to Pharma and Biotech Daily, stay tuned for more updates.